SpyGlass Pharma (SGP) priced 9.375M shares $16.00, the midpoint of the $15.00-$17.00 range. Jefferies, Leerink, Citi and Stifel are acting as joint book running managers for the offering. SpyGlass Pharma is a late-stage biopharmaceutical company whose drug delivery technology is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGP: